Edition:
United States

Cellmid Ltd (CDY.AX)

CDY.AX on Australia Stock Exchange

0.03AUD
24 Mar 2017
Change (% chg)

$0.00 (+10.34%)
Prev Close
$0.03
Open
$0.03
Day's High
$0.03
Day's Low
$0.03
Volume
11,314,849
Avg. Vol
1,321,928
52-wk High
$0.04
52-wk Low
$0.02

Latest Key Developments (Source: Significant Developments)

Cellmid says European Midkine patent for Alopecia allowed
Monday, 6 Feb 2017 05:16pm EST 

Cellmid Ltd - :Cellmid's European Midkine patent for Alopecia allowed.  Full Article

Cellmid raises $4 mln to leverage sales growth
Wednesday, 29 Jul 2015 06:31pm EDT 

Cellmid:Money raised by accepting subscriptions for new fully paid ordinary shares in company at $0.03 per placement share.Under the placement, about 133 million fully paid ordinary shares will be issued at a price of $0.03, representing $4.0 million.  Full Article

Cellmid Ltd announces US patent for anti-midkine antibodies granted
Sunday, 28 Jun 2015 09:10pm EDT 

Cellmid Ltd:Says US Patent Office has issued a notice of allowance for Cellmid's patent application 12/312,522 entitled "Antibody recognising C-domain of midkine".Says granted claims cover antibodies and antibody fragments which bind to the important functional C-domain of growth factor midkine (MK).  Full Article

Cellmid Ltd's humanised midkine antibody drug is safe in toxicology studies
Sunday, 14 Jun 2015 08:33pm EDT 

Cellmid Ltd:Says that it has completed first ever formal pre-clinical toxicology studies for anti-midkine (MK) therapeutic molecule, with no mortalities, morbidities, dose limiting toxicities or organ damage evident in any treated animal at any dose.Says single doses of CAB102 were administered by intravenous infusion at 3 dose levels, 10, 50 or 100mg/kg.Says animals were monitored for 14 days post-dose for clinical observations, morbidities, weight changes, clinical chemistries and blood cell counts.Says that at study end necropsies were performed with all major organs examined for gross abnormalities.Says histological specimens were also collected for further investigation in case of any irregularities.  Full Article

Cellmid Ltd announces hair growth product supply agreement signed with Taiwanese Maywufa
Monday, 1 Jun 2015 09:03pm EDT 

Cellmid Ltd:Signed important private label supply agreement with listed Taiwanese healthcare business, Maywufa Company Ltd.Says this is Cellmid's first private label entry into the estimated $5 billion global hair growth and anti-aging hair care market.Says according to terms of agreement Cellmid, through its wholly owned subsidiary Advangen Inc., will manufacture and sell to Maywufa FGF5 inhibitor hair growth products under their brand.Says other terms of agreement are not disclosed.  Full Article

Cellmid Limited announces issue of shares
Monday, 18 May 2015 11:24pm EDT 

Cellmid Limited:Issues 2,255,384 fully paid ordinary shares.  Full Article

Cellmid Limited announces positive clinical results
Tuesday, 14 Apr 2015 09:31pm EDT 

Cellmid Limited:Says it has received positive results in all measured areas of its independently conducted, randomized, blinded and placebo controlled human clinical study of the évolis ONE formulation.Says the 32 patient study was conducted with Cellmid’s novel and proprietary FGF5 inhibitor formulation, évolis ONE, which is a fully optimised, GMP manufactured and market ready product.  Full Article

More From Around the Web

BRIEF-Cellmid says European Midkine patent for Alopecia allowed

* Cellmid's European Midkine patent for Alopecia allowed Source text for Eikon: Further company coverage:

No consensus analysis data available.